🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise around the world, with estimates suggesting more than 82 million instances per year. Notably increased rates are seen in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Secure Authorization

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to data detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an comparable level with the existing first-line therapy, which combines a dual-drug approach. The research involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have shared positive views. The availability of a one-pill regimen like this is seen as a "revolutionary step" for gonorrhoea control. This is deemed crucial to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea worldwide.